Sep 07, 2022 / 07:30PM GMT
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
So good afternoon. Welcome back. Delighted to introduce our session. We have from Lilly, Dan Skovronsky, the CSO, CMO and President of Lilly R&D. Did I get that right?
Daniel M. Skovronsky - Eli Lilly and Company - Senior VP, Chief Scientific & Medical Officer and President of Lilly Research Labs
Yes, perfect.
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
All 3, excellent. I'm doing well. So we have about 40 minutes. I'd like to make this session interactive. Lilly currently enjoys by far the highest multiple of the group, which I'm sure everyone in this room knows.
Questions and Answers:
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MDMaybe just to kick off on donanemab, which is a program. We obviously have lecanemab data upcoming. We have the data from